Prazosin

Summary

Prazosin (CHEMBL2) is an approved small-molecule antihypertensive agent (ATC C02CA01) targeting ADRA1A, ADRA1B, and ADRA1D; indicated across 10 conditions including hypertensive disorder and post-traumatic stress disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02CA01
• Targets: 6 (ADRA1A, ADRA1B, ADRA1D…)
• Indications: 10 conditions
• Clinical trials: 47
• Chemistry: 383.4 Da · C19H21N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2
Name	Prazosin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4893
ChEBI	CHEBI:8364
ATC	C02CA01
Molecular formula	C19H21N5O4
Molecular weight	383.4
InChIKey	IENZQIKPVFGBNW-UHFFFAOYSA-N

SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC

IUPAC name: [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone

ChEBI definition: A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Pharmacological roles (ChEBI): antihypertensive agent, α-adrenergic antagonist, EC 3.4.21.26 (prolyl oligopeptidase) inhibitor.

Also known as: CP-122991, Prazosin, Prazosina, Prazosine, [3H]prazosin, Prazocin, SID11111665, SID11112649, SID11112650, SID11113367, SID26751613, SID26751614

Parent form; salt/anhydrous children: CHEMBL1558, CHEMBL1347191

Patent coverage: 8,562 distinct patent families (31,107 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 30,775 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA1A	α1A-adrenoceptor	Inverse agonist	9.9		P35348
ADRA1B	α1B-adrenoceptor	Inverse agonist	9.9	0%	P35368
ADRA1D	α1D-adrenoceptor	Inverse agonist	10.2	0.2%	P25100
ADRA2A	α2A-adrenoceptor	Antagonist	6.5	0.1%	P08913
ADRA2B	α2B-adrenoceptor	Antagonist	7.5	0.2%	P18089
ADRA2C	α2C-adrenoceptor	Antagonist	8	0%	P18825

Broader ChEMBL bioactivity targets: 71 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Prelamin-A/C, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Thrombopoietin, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Solute carrier family 22 member 2, Multidrug and toxin extrusion protein 1.

Bioactivity

ChEMBL activities: 272 potent at pChembl ≥ 5 of 343 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15823	10.99	Kd	0.01	nM	CHEMBL_ACT_954060
ADRA1B	10.57	Ki	0.03	nM	CHEMBL_ACT_25943481
ADRA1A	10.4	Ki	0.04	nM	CHEMBL_ACT_14738659
ADRA1A	10.4	Ki	0.04	nM	CHEMBL_ACT_15187873
P15823	10.38	Kd	0.04	nM	CHEMBL_ACT_56881
ADRA1D	10.27	Ki	0.05	nM	CHEMBL_ACT_13342049
ADRA1D	10.2	Ki	0.06	nM	CHEMBL_ACT_26333245
P43140	10.15	Ki	0.07	nM	CHEMBL_ACT_1276270
P43140	10.06	Ki	0.09	nM	CHEMBL_ACT_7726216
P15823	10.01	Ki	0.1	nM	CHEMBL_ACT_577326
P15823	10	Ki	0.1	nM	CHEMBL_ACT_1758234
P15823	10	Ki	0.1	nM	CHEMBL_ACT_7726218
P18130	9.9	Ki	0.13	nM	CHEMBL_ACT_1192774
ADRA1A	9.89	Ki	0.13	nM	CHEMBL_ACT_25943479
P15823	9.82	Ki	0.15	nM	CHEMBL_ACT_1276271
P15823	9.82	Ki	0.15	nM	CHEMBL_ACT_13340338
ADRA1A	9.82	Ki	0.15	nM	CHEMBL_ACT_18699007
P15823	9.82	Ki	0.15	nM	CHEMBL_ACT_881477
P43140	9.81	Kd	0.15	nM	CHEMBL_ACT_709696
P15823	9.8	Ki	0.16	nM	CHEMBL_ACT_1067635
P15823	9.79	IC50	0.16	nM	CHEMBL_ACT_309443
P23944	9.77	Kd	0.17	nM	CHEMBL_ACT_12062930
ADRA1D	9.77	IC50	0.17	nM	CHEMBL_ACT_13336217
ADRA1D	9.77	Ki	0.17	nM	CHEMBL_ACT_19150866
P18130	9.77	Ki	0.17	nM	CHEMBL_ACT_323054
P15823	9.75	IC50	0.18	nM	CHEMBL_ACT_7726217
P15823	9.72	Ki	0.19	nM	CHEMBL_ACT_1025797
P15823	9.72	Ki	0.19	nM	CHEMBL_ACT_1088816
P15823	9.72	Ki	0.19	nM	CHEMBL_ACT_1251303
P15823	9.72	Ki	0.19	nM	CHEMBL_ACT_752331

Target pathways

Aggregated over 6 target gene(s): ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C.

Top Reactome pathways

21 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
Signaling by GPCR	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
Class A/1 (Rhodopsin-like receptors)	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
Amine ligand-binding receptors	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
GPCR downstream signalling	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
Adrenoceptors	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
GPCR ligand binding	6	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
Hemostasis	3	ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor	3	ADRA2A, ADRA2B, ADRA2C
G alpha (q) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (12/13) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (i) signalling events	3	ADRA2A, ADRA2B, ADRA2C
G alpha (z) signalling events	3	ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation	3	ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)	3	ADRA2A, ADRA2B, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Metabolism of proteins	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C

Dominant GO biological processes

GO term	Targets
signal transduction	6
G protein-coupled receptor signaling pathway	6
positive regulation of MAPK cascade	6
adrenergic receptor signaling pathway	6
cell-cell signaling	5
regulation of vasoconstriction	5
adenylate cyclase-activating adrenergic receptor signaling pathway	4
phospholipase C-activating G protein-coupled receptor signaling pathway	3
positive regulation of cytosolic calcium ion concentration	3
neuron-glial cell signaling	3
epidermal growth factor receptor signaling pathway	3
negative regulation of norepinephrine secretion	3
platelet activation	3
negative regulation of epinephrine secretion	3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	3

Indications & clinical

Indications

10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537
post-traumatic stress disorder	3	MONDO:0005146	EFO:0001358
nephrolithiasis	3	MONDO:0008171	EFO:0004253
alcohol abuse	3	MONDO:0002046	MONDO:0007079
nicotine dependence	2	MONDO:0008575	EFO:0003768
methamphetamine dependence	2	MONDO:0005419	EFO:0004701
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
anxiety	1	MONDO:0011918	EFO:0005230
alcohol withdrawal	1	MONDO:0005433	EFO:0004777

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 47.

Phase distribution

Phase	Trials
PHASE2	13
Not specified	13
PHASE4	7
PHASE3	5
PHASE1	5
PHASE1/PHASE2	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00108420	PHASE4	COMPLETED	Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance
NCT00167687	PHASE4	COMPLETED	Prazosin Alcohol Dependence IVR Study
NCT00450164	PHASE4	COMPLETED	Secondary Prophylaxis After Variceal Bleeding in Non-Responders
NCT02199652	PHASE4	COMPLETED	Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)
NCT02965027	PHASE4	COMPLETED	Prazosin for Post-Concussive Headaches
NCT03997864	PHASE4	WITHDRAWN	Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault
NCT06287905	PHASE4	UNKNOWN	A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin
NCT03539614	PHASE3	ACTIVE_NOT_RECRUITING	Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests
NCT00532493	PHASE3	COMPLETED	Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD
NCT00713739	PHASE3	UNKNOWN	Alfuzosin for Medical Expulsion Therapy of Ureteral Stones
NCT00744055	PHASE3	COMPLETED	Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
NCT00753064	PHASE3	COMPLETED	AScVS and/ or Prazosin for Scorpion Envenomation
NCT04793685	PHASE2	RECRUITING	Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
NCT06629077	PHASE2	RECRUITING	Brain Blood Vessel Responses to Changes in Blood Flow
NCT06629090	PHASE2	RECRUITING	Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort
NCT00148837	PHASE2	UNKNOWN	Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
NCT00585780	PHASE1/PHASE2	COMPLETED	Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
NCT00602186	PHASE1/PHASE2	UNKNOWN	Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction
NCT00762710	PHASE2	COMPLETED	Study of the Medication Prazosin for Alcohol Dependence
NCT01178138	PHASE2	COMPLETED	Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin
NCT01518972	PHASE2	COMPLETED	Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder
NCT01642433	PHASE2	TERMINATED	Prazosin for Smoking Cessation
NCT02322047	PHASE2	COMPLETED	Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders
NCT02431936	PHASE2	COMPLETED	Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress
NCT02966340	PHASE1/PHASE2	COMPLETED	Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
NCT03045016	PHASE2	COMPLETED	Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder
NCT03710642	PHASE2	COMPLETED	Prazosin for Agitation in Alzheimer’s Disease
NCT04365257	PHASE2	TERMINATED	Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
NCT03010995	PHASE1	WITHDRAWN	The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study
NCT03894345	PHASE1	SUSPENDED	Prazosin Use in Adults With Anxiety Disorders
NCT04967443	PHASE1	COMPLETED	Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
NCT05189977	PHASE1	TERMINATED	A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
NCT06147622	PHASE1	COMPLETED	A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine
NCT02193256	EARLY_PHASE1	COMPLETED	Varenicline + Prazosin for Heavy Drinking Smokers
NCT00161473	Not specified	COMPLETED	Alzheimer’s in Long-Term Care–Treatment for Agitation
NCT00174551	Not specified	UNKNOWN	Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD
NCT00183430	Not specified	TERMINATED	Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder
NCT00202449	Not specified	TERMINATED	Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance
NCT00240227	Not specified	TERMINATED	Prazosin for ETOH or Cocaine Craving
NCT00261729	Not specified	COMPLETED	Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

780 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ALFUZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
APRACLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
BRIMONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
CLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
DEXMEDETOMIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
INDORAMIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
LABETALOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
MOXISYLYTE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
PHENTOLAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
TERAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
TOLAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
VERAPAMIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
BUNAZOSIN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
IDAZOXAN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
LATREPIRDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
MEDETOMIDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
YOHIMBINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
CIRAZOLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
DEXNIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
IPSAPIRONE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
NIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
PIPEROXAN	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
PIZOTYLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
SPIRAMIDE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
SPIROXATRINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ZOTEPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C
BENZTROPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C